Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.49 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.45 |
| ▸ | LIPE | Q05469 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PAM | P19021 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL68851 | 0.90 | CYP4Z1 (0.62) | CYP4Z1MAPTLMNASMN1; SMN2CYP4F2 | |
| SCHEMBL6024761 | 0.85 | CYP4F2 (0.53) | CYP4Z1MAPTLMNASMN1; SMN2CYP4F2 | |
| SCHEMBL1125428 | 0.85 | ALDH1A1 (0.45) | CYP4Z1LMNASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL4733 | 0.85 | CYP1A2 (0.55) | CYP4Z1MAPTLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL7414630 | 0.84 | CYP4F2 (0.50) | CYP4Z1MAPTLMNASMN1; SMN2CYP4F2 | |
| SCHEMBL10299459 | 0.84 | CYP4Z1 (0.57) | CYP4Z1MAPTLMNASMN1; SMN2CYP4F2 | |
| SCHEMBL68930 | 0.84 | CYP4Z1 (0.57) | CYP4Z1MAPTLMNASMN1; SMN2CYP4F2 | |
| SCHEMBL1107146 | 0.84 | CYP4Z1 (0.57) | CYP4Z1MAPTLMNASMN1; SMN2CYP4F2 | |
| SCHEMBL6057577 | 0.84 | CYP4F2 (0.59) | CYP4Z1MAPTLMNASMN1; SMN2CYP4F2 | |
| SCHEMBL6207253 | 0.82 | CYP4Z1 (0.55) | CYP4Z1MAPTLMNASMN1; SMN2CYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111954848-B | Photosensitive resin composition, cured product, insulating material, resin material for solder resist, and resist member | DIC株式会社 | 2024-05-03 | — | — | CN | disclosed |
| CN-111183130-B | Benzoheterocycle derivatives and pharmaceutical compositions containing the same | 恒翼生物医药(上海)股份有限公司 | 2023-10-20 | — | — | CN | disclosed |
| CN-116102543-A | GLP-1R agonist, synthesis method and application thereof | 江南大学 | 2023-05-12 | — | — | CN | disclosed |
| CN-110234656-B | Exonucleotidase inhibitors and methods of use thereof | 卡利泰拉生物科技公司 | 2023-02-28 | — | — | CN | disclosed |
| US-20230002437-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | ANTENGENE THERAPEUTICS LIMITED (CN) | 2023-01-05 | — | — | US | disclosed |
| WO-2023275796-A1 | HETEROCYCLIC DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE 3 INHIBITORS | NOVARTIS AG (CH) | 2023-01-05 | — | — | WO | disclosed |
| US-11208414-B2 | Ectonucleotidase inhibitors and methods of use thereof | CALITHERA BIOSCIENCES, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-11174261-B2 | — | — | 2021-11-16 | — | — | US | disclosed |
| US-11091421-B2 | Benzene fused heterocyclic derivative and pharmaceutical composition comprising the same | TAIWANJ PHARMACEUTICALS CO., LTD. (TW) | 2021-08-17 | — | — | US | disclosed |
| US-11079675-B2 | Compound, photocurable composition, cured product of same, printing ink, and printed matter curing the printing ink | DIC CORPORATION (JP) | 2021-08-03 | — | — | US | disclosed |
| EP-1255758-A1 | APOPTOSIS-INDUCING COMPOUNDS | THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN (IE) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001058904-A9 | APOPTOSIS-INDUCING COMPOUNDS | TRINITY COLLEGE DUBLIN (IE) | 2002-02-21 | — | — | WO | disclosed |
| WO-2001058904-A1 | APOPTOSIS-INDUCING COMPOUNDS | THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN (IE) | 2001-08-16 | — | — | WO | disclosed |
| US-6028080-A | Quinolin-2-(1H)-ones | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2000-02-22 | — | — | US | disclosed |
| WO-1999056736-A2 | APOPTOSIS-INDUCING COMPOUNDS | THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN (IE) | 1999-11-11 | — | — | WO | disclosed |
| US-5021414-A | Antiestrogen | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-06-04 | — | — | US | disclosed |
| US-4904661-A | ANTIESTROGENS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-02-27 | — | — | US | disclosed |
| US-4732912-A | ANTIESTROGENS, ANTITUMOR AGENTS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-03-22 | — | — | US | disclosed |
| EP-0124369-B1 | PHENOL DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-06-24 | — | — | EP | disclosed |
| EP-0124369-A1 | Phenol derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1984-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11174261-B2 | — | ENTPD5, NT5E, ENTPD1 | CYP4Z1 2521/4885MAPT 4828/4885LMNA 2528/4885 |
| US-11208414-B2 | Ectonucleotidase inhibitors and methods of use thereof | ENTPD5, NT5E, ENTPD1 | CYP4Z1 2614/4885MAPT 4808/4885LMNA 2056/4885 |
| US-11079675-B2 | Compound, photocurable composition, cured product of same, printing ink, and printed matter curing the printing ink | EPB41, F12, CDK1 | CYP4Z1 913/4885MAPT 1365/4885LMNA 740/4885 |
| US-11091421-B2 | Benzene fused heterocyclic derivative and pharmaceutical composition comprising the same | RORB, RORC, NR3C1 | CYP4Z1 15/4885MAPT 4302/4885LMNA 4142/4885 |
| US-20230002437-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | NT5E, ENTPD5, NT5C2 | CYP4Z1 2211/4885MAPT 4512/4885LMNA 2684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.